$SWTX -13.7% [TD Cowen sees "some disappointment" with lack of SpringWorks Therapeutics M&A news:

"With two fully owned drugs globally and profitability seen in the first half of FY26," TD does anticipate that $SWTX “could be a takeout with time as the value of both assets becomes clearer to strategics.”  

TD Cowen has a Buy rating and $63 price target on the shares]